BLFS
NASDAQ · Life Sciences Tools & Services
Biolife Solutions Inc
$38.61
+1.31 (+3.51%)
Financial Highlights (FY 2026)
Revenue
98.57M
Net Income
-4,706,424
Gross Margin
64.6%
Profit Margin
-4.8%
Rev Growth
-15.9%
D/E Ratio
0.01
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 64.6% | 64.6% | 54.8% | 54.8% |
| Operating Margin | -17.3% | -15.5% | 5.1% | 5.3% |
| Profit Margin | -4.8% | -4.5% | 4.6% | 6.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 98.57M | 117.22M | 1.26B | 1.01B |
| Gross Profit | 63.64M | 75.68M | 690.00M | 556.09M |
| Operating Income | -17,013,308 | -18,209,034 | 63.84M | 54.08M |
| Net Income | -4,706,424 | -5,037,200 | 58.21M | 63.51M |
| Gross Margin | 64.6% | 64.6% | 54.8% | 54.8% |
| Operating Margin | -17.3% | -15.5% | 5.1% | 5.3% |
| Profit Margin | -4.8% | -4.5% | 4.6% | 6.3% |
| Rev Growth | -15.9% | -15.9% | +9.5% | +17.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 12.49M | 12.49M | 538.01M | 550.42M |
| Total Equity | 931.98M | 931.98M | 666.68M | 636.38M |
| D/E Ratio | 0.01 | 0.01 | 0.81 | 0.86 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -16,741,564 | -18,913,647 | 80.62M | 66.64M |
| Free Cash Flow | — | — | 44.34M | 36.90M |